COSCIENS Biopharma Inc (CSCI) FinancialsCSCICOSCIENS Biopharma Inc

COSCIENS Biopharma Inc (CSCI) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Active Ingredients, accounting for 92.5% of total sales, equivalent to $1.39M. Another important revenue stream is Biopharmaceutical segment. Understanding this composition is critical for investors evaluating how CSCI navigates market cycles within the Biotechnology & Medical Research industry.

Evaluating the bottom line, COSCIENS Biopharma Inc maintains a gross margin of 35.43%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -85.59%, while the net margin is -98.25%. These profitability ratios, combined with a Return on Equity (ROE) of -113.08%, provide a clear picture of how effectively CSCI converts its operational activities into shareholder value.

In the context of the broader market, CSCI competes directly with industry leaders such as SNGX and NXTC. With a market capitalization of N/A, it holds a significant position in the sector. When comparing efficiency, CSCI's gross margin of 35.43% stands against SNGX's N/A and NXTC's N/A. Such benchmarking helps identify whether COSCIENS Biopharma Inc is trading at a premium or discount relative to its financial performance.